Marinomed Biotech AG is a biopharmaceutical company. It specializes in the development of innovative products based on patent protected technology platforms in the field of respiratory and ophthalmic diseases. Marinomed has received multiple prestigious research awards for its activities.
Marinomed has developed two platforms to date: the Marinosolv® technology platform and the Carragelose® platform.
The Marinosolv® technology platform enhances the efficacy of hardly soluble compounds. This innovative technology has the potential to sustainably change a number of therapies for allergies and auto-immune diseases. The flagship product Budesolv is currently being investigated in a pivotal Phase III approval study.
The Carragelose® platform is already used in six different products to treat viral infections of the respiratory tract, which are sold globally via the company’s partners.